Premium
Labcorp Holdings Inc (0JSY)
LSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -5,90k | 1,50M | Automatic Disposition | 254,50 | 107,23k | -5,22% |
| 2026-03-26 | Mr. Adam H. SchechterPresident, CEO & Chairman | -26,11k | 7,01M | Sale to Issuer | 268,38 | 113,14k | -18,75% |
| 2026-03-26 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | -2,88k | 772,67k | Sale to Issuer | 268,38 | 5,19k | -35,70% |
| 2026-03-26 | Mr. Mark S. SchroederInitié | -6,07k | 1,63M | Sale to Issuer | 268,38 | 12,68k | -32,37% |
| 2026-03-26 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -4,91k | 1,32M | Sale to Issuer | 268,38 | 36,49k | -11,85% |
| 2026-03-27 | Mr. Peter J. WilkinsonSenior VP & CAO | -1,63k | 436,09k | Automatic Disposition | 267,05 | 1,85k | -46,86% |
| 2026-03-26 | Mr. Peter J. WilkinsonSenior VP & CAO | -755,00 | 202,63k | Sale to Issuer | 268,38 | 1,85k | -28,96% |
| 2026-03-26 | Mr. Bryan T. VaughnEVP & President of Diagnostics | -451,00 | 121,04k | Sale to Issuer | 268,38 | 6,75k | -6,27% |
| 2026-03-26 | Ms. Sandra D. van der VaartInitié | -2,72k | 730,53k | Sale to Issuer | 268,38 | 6,24k | -30,38% |
| 2026-03-26 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | -1,84k | 492,75k | Sale to Issuer | 268,38 | 7,88k | -18,90% |
| 2026-03-26 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | -382,00 | 102,52k | Sale to Issuer | 268,38 | 5,06k | -7,01% |
| 2026-03-27 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -839,00 | 224,05k | Automatic Disposition | 267,05 | 3,62k | -18,82% |
| 2026-03-26 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -711,00 | 190,82k | Sale to Issuer | 268,38 | 3,62k | -16,42% |
| 2026-03-26 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | -451,00 | 121,04k | Sale to Issuer | 268,38 | 4,58k | -8,97% |
| 2026-03-26 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | -481,00 | 129,09k | Sale to Issuer | 268,38 | 4,85k | -9,02% |
| 2026-03-03 | Mr. Adam H. SchechterPresident, CEO & Chairman | -8,71k | 2,44M | Vente | 279,96 | 80,77k | -9,73% |
| 2026-02-27 | Ms. Sandra D. van der VaartInitié | -547,54 | 156,00k | Vente | 284,91 | 2,58k | -17,51% |
| 2026-02-24 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -1,50k | 429,46k | Vente | 286,31 | 30,11k | -4,75% |
| 2026-02-19 | Mr. Peter J. WilkinsonSenior VP & CAO | -666,00 | 185,11k | Automatic Disposition | 277,94 | 1,85k | -26,45% |
| 2026-02-11 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | 147,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,72k | 2,64% |
| 2026-02-11 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | -83,00 | 24,06k | Derivative Exercise and Sale | 289,89 | 5,72k | - |
| 2026-02-11 | Mr. Peter J. WilkinsonSenior VP & CAO | 490,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,52k | 24,16% |
| 2026-02-11 | Mr. Peter J. WilkinsonSenior VP & CAO | -206,00 | 59,72k | Derivative Exercise and Sale | 289,89 | 2,52k | - |
| 2026-02-11 | Ms. Julia A. WangCFO & Exec. VP | 615,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,82k | 51,16% |
| 2026-02-11 | Ms. Julia A. WangCFO & Exec. VP | -245,00 | 71,02k | Derivative Exercise and Sale | 289,89 | 1,82k | - |
| 2026-02-11 | Ms. Sandra D. van der VaartInitié | 277,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,13k | 9,72% |
| 2026-02-11 | Ms. Sandra D. van der VaartInitié | -99,00 | 28,70k | Derivative Exercise and Sale | 289,89 | 3,13k | - |
| 2026-02-11 | Mr. Bryan T. VaughnEVP & President of Diagnostics | 230,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,61k | 4,27% |
| 2026-02-11 | Mr. Bryan T. VaughnEVP & President of Diagnostics | -93,00 | 26,96k | Derivative Exercise and Sale | 289,89 | 5,61k | - |
| 2026-02-11 | Mr. Mark S. SchroederInitié | 547,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,47k | 9,23% |
| 2026-02-11 | Mr. Mark S. SchroederInitié | -259,00 | 75,08k | Derivative Exercise and Sale | 289,89 | 6,47k | - |
| 2026-02-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | 2,14k | 0,00 | Derivative Exercise and Retained Stock | - | 89,48k | 2,44% |
| 2026-02-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -1,52k | 440,92k | Derivative Exercise and Sale | 289,89 | 89,48k | - |
| 2026-02-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -5,27k | 1,50M | Automatic Disposition | 284,38 | 89,48k | -5,57% |
| 2026-02-11 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | 162,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,11k | 4,11% |
| 2026-02-11 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | -68,00 | 19,71k | Derivative Exercise and Sale | 289,89 | 4,11k | - |
| 2026-02-11 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | 154,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,44k | 4,68% |
| 2026-02-11 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | -62,00 | 17,97k | Derivative Exercise and Sale | 289,89 | 3,44k | - |
| 2026-02-11 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | 86,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,78k | 3,19% |
| 2026-02-11 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -157,00 | 45,56k | Derivative Exercise and Sale | 289,89 - 290,42 | 2,78k | - |
| 2026-02-11 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | 247,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,46k | 20,36% |
| 2026-02-11 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | -109,00 | 31,60k | Derivative Exercise and Sale | 289,89 | 1,46k | - |
| 2026-02-11 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | 529,00 | 0,00 | Derivative Exercise and Retained Stock | - | 31,61k | 1,70% |
| 2026-02-11 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -211,00 | 61,17k | Derivative Exercise and Sale | 289,89 | 31,61k | - |
| 2026-02-11 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | 265,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,15k | 6,82% |
| 2026-02-11 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | -138,00 | 40,00k | Derivative Exercise and Sale | 289,89 | 4,15k | - |
| 2026-02-11 | Dr. Paul B. RothmanIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,57k | 53,58% |
| 2026-02-11 | Ms. Kathryn E. WengelIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,13k | 27,72% |
| 2026-02-11 | Ms. Richelle P. ParhamIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,37k | 36,33% |
| 2026-02-11 | Mr. Peter M. NeupertIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 13,78k | 6,96% |
| 2026-02-11 | Dr. Garheng Albert KongVice Chair & Lead Independent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 13,74k | 6,98% |
| 2026-02-11 | Ms. Kirsten Marie KliphouseIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,16k | 39,64% |
| 2026-02-11 | Mr. Jeffrey A. DavisIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,46k | 19,66% |
| 2026-02-11 | Ms. Kerrii B. AndersonIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 9,85k | 10,02% |
| 2026-02-10 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -91,00 | 25,19k | Automatic Disposition | 276,79 | 2,70k | -3,27% |
| 2026-02-06 | Ms. Julia A. WangCFO & Exec. VP | 639,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,20k | 113,50% |
| 2026-02-06 | Ms. Julia A. WangCFO & Exec. VP | -254,00 | 70,41k | Derivative Exercise and Sale | 277,20 | 1,20k | - |
| 2026-02-06 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | 909,00 | 0,00 | Derivative Exercise and Retained Stock | - | 31,08k | 3,01% |
| 2026-02-06 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -389,00 | 107,26k | Derivative Exercise and Sale | 274,01 - 277,20 | 31,08k | - |
| 2026-02-06 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | 217,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,94k | 5,82% |
| 2026-02-06 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | -112,00 | 30,88k | Derivative Exercise and Sale | 274,01 - 277,20 | 3,94k | - |
| 2026-02-06 | Mr. Adam H. SchechterPresident, CEO & Chairman | 5,04k | 0,00 | Derivative Exercise and Retained Stock | - | 92,62k | 5,76% |
| 2026-02-06 | Mr. Adam H. SchechterPresident, CEO & Chairman | -2,67k | 734,98k | Derivative Exercise and Sale | 274,01 - 277,20 | 92,62k | - |
| 2026-02-06 | Mr. Peter J. WilkinsonSenior VP & CAO | 176,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,03k | 9,50% |
| 2026-02-06 | Mr. Peter J. WilkinsonSenior VP & CAO | -91,00 | 25,08k | Derivative Exercise and Sale | 274,01 - 277,20 | 2,03k | - |
| 2026-02-06 | Mr. Mark S. SchroederInitié | 966,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,93k | 19,48% |
| 2026-02-06 | Mr. Mark S. SchroederInitié | -458,00 | 126,26k | Derivative Exercise and Sale | 274,01 - 277,20 | 5,93k | - |
| 2026-02-06 | Ms. Sandra D. van der VaartInitié | 546,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,85k | 23,71% |
| 2026-02-06 | Ms. Sandra D. van der VaartInitié | -194,00 | 53,48k | Derivative Exercise and Sale | 274,01 - 277,20 | 2,85k | - |
| 2026-02-06 | Mr. Bryan T. VaughnEVP & President of Diagnostics | 236,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,38k | 4,59% |
| 2026-02-06 | Mr. Bryan T. VaughnEVP & President of Diagnostics | -122,00 | 33,62k | Derivative Exercise and Sale | 274,01 - 277,20 | 5,38k | - |
| 2026-02-06 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | 269,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,79k | 10,68% |
| 2026-02-06 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -261,00 | 71,94k | Derivative Exercise and Sale | 274,01 - 277,20 | 2,79k | - |
| 2026-02-06 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | 236,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,29k | 7,73% |
| 2026-02-06 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | -122,00 | 33,62k | Derivative Exercise and Sale | 274,01 - 277,20 | 3,29k | - |
| 2026-02-06 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | 463,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,21k | 61,73% |
| 2026-02-06 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | -231,00 | 63,68k | Derivative Exercise and Sale | 274,01 - 277,20 | 1,21k | - |
| 2026-02-06 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | 273,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,58k | 5,15% |
| 2026-02-06 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | -172,00 | 47,42k | Derivative Exercise and Sale | 274,01 - 277,20 | 5,58k | - |
| 2026-02-06 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | 289,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,88k | 8,04% |
| 2026-02-06 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | -180,00 | 49,55k | Derivative Exercise and Sale | 274,01 - 277,20 | 3,88k | - |
| 2025-11-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -5,75k | 1,51M | Automatic Disposition | 262,75 | 87,57k | -6,16% |
| 2025-11-01 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | 191,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,59k | 5,61% |
| 2025-11-01 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | -179,00 | 46,15k | Derivative Exercise and Sale | 257,84 | 3,59k | - |
| 2025-11-01 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | 263,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,73k | 7,59% |
| 2025-11-01 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | -107,00 | 27,59k | Derivative Exercise and Sale | 257,84 | 3,73k | - |
| 2025-10-31 | Ms. Richelle P. ParhamIndependent Director | -7,01k | 1,78M | Vente | 254,28 | 2,47k | -73,95% |
| 2025-08-13 | Ms. Sandra D. van der VaartInitié | -3,90k | 546,40k | Derivative Exercise and Sale | 131,43 - 271,42 | 2,27k | - |
| 2025-08-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -5,64k | 1,51M | Automatic Disposition | 266,78 | 93,32k | -5,70% |
| 2025-07-30 | Dr. D. Gary GillilandInitié | -2,00k | 529,90k | Vente | 264,95 | 6,66k | -23,11% |
| 2025-07-29 | Mr. Peter J. WilkinsonSenior VP & CAO | -202,00 | 52,73k | Vente | 261,01 - 261,04 | 1,85k | -9,83% |
| 2025-07-24 | Ms. Kerrii B. AndersonIndependent Director | -3,50k | 980,00k | Automatic Disposition | 280,00 | 8,95k | -28,10% |
| 2025-07-01 | Ms. Kerrii B. AndersonIndependent Director | -500,00 | 132,50k | Automatic Disposition | 265,00 | 12,45k | -3,86% |
| 2025-06-11 | Ms. Kerrii B. AndersonIndependent Director | -500,00 | 130,00k | Automatic Disposition | 260,00 | 12,95k | -3,72% |
| 2025-06-03 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -2,00k | 494,00k | Vente | 247,00 | 30,07k | -6,24% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
